ICU Medical, Inc. (NASDAQ:ICUI) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• ICU Medical has a “Moderate Buy” consensus rating from nine analysts, with an average 12-month price target of $192.80. Recent firms raised targets to approximately $195–$200, although one analyst downgraded the stock to “hold.”
• The company exceeded quarterly expectations, reporting $2.37 in EPS versus a $1.91 estimate and revenue of $547.88 million versus $533.44 million expected. Revenue increased 0.5% year over year, and management issued fiscal 2026 EPS guidance of $8.60–$9.00.
• ICUI shares opened at $182.98, near their 12-month high of $192.85, while institutional investors own 96.1% of the stock. Several insiders recently sold shares, including executives Daniel Woolson and Christian B. Voigtlander.

Shares of ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $192.80.

Several brokerages recently weighed in on ICUI. Raymond James Financial reaffirmed a "strong-buy" rating and set a $200.00 target price on shares of ICU Medical in a research note on Friday, August 7th. Zacks Research lowered ICU Medical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Piper Sandler increased their price objective on ICU Medical from $163.00 to $195.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. Wall Street Zen upgraded ICU Medical from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 8th. Finally, BTIG Research lifted their target price on ICU Medical from $170.00 to $200.00 and gave the company a "buy" rating in a report on Friday, August 7th.

ICU Medical Price Performance

ICUI stock opened at $182.98 on Friday. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $4.57 billion, a PE ratio of 155.07, a P/E/G ratio of 2.56 and a beta of 0.74. ICU Medical has a 12-month low of $112.50 and a 12-month high of $192.85. The business's fifty day moving average price is $156.56 and its 200 day moving average price is $141.96.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The firm had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. During the same quarter in the prior year, the company earned $2.10 EPS. ICU Medical's revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, sell-side analysts anticipate that ICU Medical will post 6.51 EPS for the current year.

Insider Buying and Selling

In related news, VP Daniel Woolson sold 5,417 shares of the firm's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $181.33, for a total value of $982,264.61. Following the sale, the vice president owned 17,062 shares of the company's stock, valued at $3,093,852.46. This trade represents a 24.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Christian B. Voigtlander sold 8,929 shares of ICU Medical stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total transaction of $1,633,381.97. Following the completion of the transaction, the chief operating officer owned 37,377 shares of the company's stock, valued at $6,837,374.61. This represents a 19.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 16,974 shares of company stock valued at $3,085,844. Corporate insiders own 2.10% of the company's stock.

Institutional Investors Weigh In On ICU Medical

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of ICU Medical during the second quarter worth $550,250,000. Jupiter Topco LLC acquired a new stake in ICU Medical in the second quarter valued at $407,786,000. Millennium Management LLC raised its stake in ICU Medical by 173.4% in the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier's stock valued at $130,638,000 after buying an additional 690,694 shares in the last quarter. Norges Bank purchased a new stake in ICU Medical during the 4th quarter worth about $58,083,000. Finally, Reinhart Partners LLC. purchased a new stake in ICU Medical during the 2nd quarter worth about $46,148,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source